Belgium· BE-AMP-SAM310213-00
Optimark 500 µmol/ml
A gadoversetamide product containing gadoversetamide, registered in Belgium by Guerbet. The same ATC class is registered in 2 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Gadoversetamide is registered in 2 of 19 countries.
Countries holding a registration under ATC V08CA06 (gadoversetamide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Gadoversetamide · ATC V08CA06
2 / 19 countries
- Belgiumprice
- Finlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Gadoversetamide
- Manufacturer
- Guerbet
- Country
- Belgium (BE)
- ATC code
- V08CA06
- ATC class
- Gadoversetamide
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb2494342
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
90 interactions on record for gadoversetamide.
Graded by severity as the source publishes them — 19 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gadoversetamide · interactions on record
90 records
- 19 moderate
- 71 info
Most severe, free to view
- PindololC07AA03moderate
- PropranololC07AA05moderate
- TimololC07AA06moderate
- SotalolC07AA07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gadoversetamide in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f8176298-bd43-4243-acde-676da5df2123 GET /v1/drugs/f8176298-bd43-4243-acde-676da5df2123?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "REVOKED",
"name_en": "Optimark 500 µmol/ml",
"name_fr": "Optimark 500 µmol/ml",
"name_nl": "Optimark 500 µmol/ml",
"amp_code": "SAM310213-00",
"strengths": [
"330.9000"
],
"pack_count": 2,
"substances": [
"Gadoversetamide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Gadoversetamide",
"authorisation_numbers": [
"EU/1/07/398/007",
"EU/1/07/398/008"
]
}See everything about gadoversetamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.